After strong Q3, no $55B deals in AbbVie’s future, CEO says. But a smaller one? Maybe

Carly Helfand No Shire? No problem for AbbVie. At least, for now. FiercePharma News

Sanofi CEO Viehbacher ousted unanimously by its board

Alok Saboo FierceBiotech News

Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug

Emily Wasserman Amid growing discontent from Big Pharma companies over India's patent-busting policies, generics maker Cipla is petitioning the country's government to revoke ...

Novo Nordisk bets another $130M on diabetes R&D with new Danish hub

Damian Garde Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $ 130 million project that will expand its wide footprint in diabetes research. FierceBiotech ...

Boehringer gets NICE nod for Pradaxa for DVT/PE in U.K.

Eric Palmer Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has ...

Impax cans 25% of its R&D staff in a cost-cutting gambit

Damian Garde Impax Laboratories is slashing its R&D payroll and moving away from early-stage research, a move designed to save cash in the midst of a costly transition. FierceBiotech ...

Impax cuts nearly 50 employees to save money

Eric Palmer Impax Laboratories, which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D ...

Novartis sets sights on Philly amid a sweeping CAR-T collaboration

Damian Garde Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers ...

Express Scripts ready to favor AbbVie hep C prospect–provided it undercuts Gilead

Carly Helfand Express Scripts–which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs–says it may quickly change ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS